CN112771043A - 取代吡唑稠环类衍生物及其制备方法和应用 - Google Patents

取代吡唑稠环类衍生物及其制备方法和应用 Download PDF

Info

Publication number
CN112771043A
CN112771043A CN201980064157.1A CN201980064157A CN112771043A CN 112771043 A CN112771043 A CN 112771043A CN 201980064157 A CN201980064157 A CN 201980064157A CN 112771043 A CN112771043 A CN 112771043A
Authority
CN
China
Prior art keywords
radical
membered
group
methyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980064157.1A
Other languages
English (en)
Other versions
CN112771043B (zh
Inventor
王志健
钟俊
王雪冰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Zhijianjinrui Biomedical Technology Co ltd
Original Assignee
Beijing Zhijianjinrui Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Zhijianjinrui Biomedical Technology Co ltd filed Critical Beijing Zhijianjinrui Biomedical Technology Co ltd
Publication of CN112771043A publication Critical patent/CN112771043A/zh
Application granted granted Critical
Publication of CN112771043B publication Critical patent/CN112771043B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

涉及药物化学领域，主要涉及式I所示的化合物、其立体异构体、消旋体、互变异构体、同位素标记物、氮氧化物、或其药学上可接受的盐及其制备方法和在制备用于治疗RET激酶介导的疾病的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201980064157.1A 2018-09-30 2019-09-30 取代吡唑稠环类衍生物及其制备方法和应用 Active CN112771043B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018111624971 2018-09-30
CN201811162497 2018-09-30
PCT/CN2019/109502 WO2020064009A1 (zh) 2018-09-30 2019-09-30 取代吡唑稠环类衍生物及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN112771043A true CN112771043A (zh) 2021-05-07
CN112771043B CN112771043B (zh) 2023-04-28

Family

ID=69950354

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201910942753.7A Active CN110964008B (zh) 2018-09-30 2019-09-30 取代吡唑稠环类衍生物及其制备方法和应用
CN201980064157.1A Active CN112771043B (zh) 2018-09-30 2019-09-30 取代吡唑稠环类衍生物及其制备方法和应用
CN202210125578.4A Active CN114380825B (zh) 2018-09-30 2019-09-30 取代吡唑稠环类衍生物及其制备方法和应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910942753.7A Active CN110964008B (zh) 2018-09-30 2019-09-30 取代吡唑稠环类衍生物及其制备方法和应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210125578.4A Active CN114380825B (zh) 2018-09-30 2019-09-30 取代吡唑稠环类衍生物及其制备方法和应用

Country Status (6)

Country Link
US (1) US20210379056A1 (zh)
EP (1) EP3845531A4 (zh)
JP (1) JP2022508533A (zh)
KR (1) KR20210070286A (zh)
CN (3) CN110964008B (zh)
WO (1) WO2020064009A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202108582A (zh) * 2019-05-14 2021-03-01 大陸商上海翰森生物醫藥科技有限公司 含二並環類衍生物抑制劑、其製備方法和應用
WO2021023209A1 (zh) * 2019-08-05 2021-02-11 北京志健金瑞生物医药科技有限公司 含氮多环稠环类化合物，其药物组合物、制备方法和用途
WO2021057963A1 (zh) * 2019-09-29 2021-04-01 广东东阳光药业有限公司 一种ret抑制剂、其药物组合物及其用途
CN112851664B (zh) * 2019-11-12 2024-03-29 浙江海正药业股份有限公司 吡唑[1,5-a]吡啶-3-腈化合物及其在医药上的用途
US20230095530A1 (en) * 2019-12-27 2023-03-30 TYK Medicines, Inc Compound used as ret kinase inhibitor and application thereof
TW202202501A (zh) * 2020-04-17 2022-01-16 美商絡速藥業公司 結晶ret抑制劑
CA3191183A1 (en) * 2020-08-20 2022-02-24 Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. Heteroaromatic ring compound as ret kinase inhibitor, and preparation and use thereof
US20230365596A1 (en) * 2020-09-29 2023-11-16 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory Crystal forms of pyridopyrazole compounds and preparation method therefor
WO2022083741A1 (zh) * 2020-10-23 2022-04-28 上海辉启生物医药科技有限公司 吡唑并吡啶类化合物或其盐及其制备方法和用途
TWI818424B (zh) * 2021-02-08 2023-10-11 大陸商北京志健金瑞生物醫藥科技有限公司 含氮多環稠環類化合物，其藥物組合物、製備方法和用途
CN115594678A (zh) * 2021-07-09 2023-01-13 北京志健金瑞生物医药科技有限公司（Cn） 含氮多环稠环类化合物的制备方法及其中间体和用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180133207A1 (en) * 2016-10-10 2018-05-17 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TW201825488A (zh) * 2016-10-10 2018-07-16 美商亞雷生物製藥股份有限公司 作為pet激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136661A1 (en) * 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
CN108349969A (zh) * 2015-07-16 2018-07-31 阵列生物制药公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡啶化合物
WO2019075108A1 (en) * 2017-10-10 2019-04-18 Metcalf Andrew T CRYSTALLINE FORMS
WO2019075114A1 (en) * 2017-10-10 2019-04-18 Mark Reynolds FORMULATIONS COMPRISING 6- (2-HYDROXY-2-METHYLPROPOXY) -4- (6- (6 - ((6-METHOXYPYRIDIN-3-YL) METHYL) -3,6-DIAZABICYCLO [3.1.1] HEPTAN-3- YL) PYRIDIN-3-YL) PYRAZOLO [1,5-A] pYRIDINE-3-carbonitrile

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
CN103814020B (zh) * 2011-06-17 2017-07-14 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) * 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
TWI783057B (zh) * 2017-10-10 2022-11-11 美商絡速藥業公司 製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108349969A (zh) * 2015-07-16 2018-07-31 阵列生物制药公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡啶化合物
US20180133207A1 (en) * 2016-10-10 2018-05-17 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TW201825488A (zh) * 2016-10-10 2018-07-16 美商亞雷生物製藥股份有限公司 作為pet激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136661A1 (en) * 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
WO2019075108A1 (en) * 2017-10-10 2019-04-18 Metcalf Andrew T CRYSTALLINE FORMS
WO2019075114A1 (en) * 2017-10-10 2019-04-18 Mark Reynolds FORMULATIONS COMPRISING 6- (2-HYDROXY-2-METHYLPROPOXY) -4- (6- (6 - ((6-METHOXYPYRIDIN-3-YL) METHYL) -3,6-DIAZABICYCLO [3.1.1] HEPTAN-3- YL) PYRIDIN-3-YL) PYRAZOLO [1,5-A] pYRIDINE-3-carbonitrile

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
《STN REGISTER》: "RN 2222758-45-2，RN 2222758-41-8， RN 2222758-39-4，RN 2222758-12-3，RN 2222758-09-8，RN 2222758-07-6，RN 2222758-02-1", 《STN REGISTER》 *

Also Published As

Publication number Publication date
KR20210070286A (ko) 2021-06-14
CN112771043B (zh) 2023-04-28
US20210379056A1 (en) 2021-12-09
EP3845531A1 (en) 2021-07-07
CN114380825A (zh) 2022-04-22
CN114380825B (zh) 2024-02-13
CN110964008B (zh) 2021-12-21
JP2022508533A (ja) 2022-01-19
WO2020064009A1 (zh) 2020-04-02
CN110964008A (zh) 2020-04-07
EP3845531A4 (en) 2021-11-24

Similar Documents

Publication Publication Date Title
CN110964008B (zh) 取代吡唑稠环类衍生物及其制备方法和应用
TWI753892B (zh) 作為ｔａｍ抑制劑之吡咯并三嗪化合物
WO2020216371A1 (zh) Egfr抑制剂及其应用
CN107531690B (zh) 用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物
JP6993985B2 (ja) イソキノリン－３イル－カルボキサミドならびにその調製および使用の方法
CN108699057B (zh) 5-取代的2-(吗啉-4-基)-1,7-萘啶
WO2020239077A1 (zh) 含氮杂环类衍生物调节剂、其制备方法和应用
CN107857755B (zh) 作为trka激酶抑制剂的n-吡咯烷基、n′-吡唑基-脲、硫脲、胍和氰基胍化合物
TW202016109A (zh) 作為hpk1抑制劑的吡咯並[2,3-b]吡啶或吡咯並[2,3-b]吡嗪及其用途
TWI763683B (zh) 作爲PDE1抑制劑之1H-吡唑并[4,3-b]吡啶
KR20170040300A (ko) 2-(모르폴린-4-일)-l,7-나프티리딘
TW201713641A (zh) 經取代之喹喏啉衍生物
TW201247673A (en) Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders
CN113490670B (zh) 含氮多环稠环类化合物,其药物组合物、制备方法和用途
JP2023511096A (ja) タンパク質キナ－ゼ阻害活性を有する７－アミノ－３，４－ジヒドロピリミドピリミジン－２－オン誘導体およびこれを含む治療用薬学組成物
TWI818424B (zh) 含氮多環稠環類化合物，其藥物組合物、製備方法和用途
CN111465410A (zh) 包括施用1h-吡唑并[4,3-b]吡啶的组合治疗
KR20200060269A (ko) Irak4 저해제로서 신규의 삼중고리 화합물
CN113423707A (zh) Erk抑制剂及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant